Molecular biology of microRNA-515 during tumor progression

MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are recognized as the central players in cancer biology, where their deregulation can drive tumor initiation and progression. Their importance in the clinic is rapidly growing, as miRNA signatures offer valuable biomarkers for diagnosis, prognosis, and prediction of therapeutic response, while miRNA-based therapeutics are entering clinical trials. Among cancer-associated miRNAs, miR-515 a member of the primate-specific chromosome 19 miRNA cluster (C19MC) has drawn attention for its dual behavior in human malignancies. Depending on the cellular context and tumor type, miR-515 can function either as an oncogene or as a tumor suppressor by targeting a broad network of transcripts involved in cell proliferation, apoptosis, and invasion. Mechanistically, it modulates key oncogenic pathways such as MAPK, Wnt/β-catenin, and PI3K/AKT and has been implicated in drug resistance. Clinically, altered miR-515 expression in tissues and circulating specimens has been correlated with clinicopathological features and patient outcomes in several retrospective studies, suggesting potential as a minimally invasive biomarker for early detection and prognostic stratification. However, prospective validation in large, independent cohorts is still required before clinical implementation. This review delineates the molecular underpinnings and contrasting roles of miR-515, emphasizing its emerging clinical applications and the challenges of harnessing its regulatory functions for precision oncology.